Major Depressive Disorder
When added to an antidepressant in adult MDD patients, VRAYLAR delivers
The Power of Both
Proven efficacy* and well-established tolerability†
Learn about VRAYLAR in MDDBipolar I Disorder
Full-Spectrum Relief
For all bipolar I symptoms in depressive and acute manic or mixed episodes in adults
Learn about VRAYLAR in BP-IThe First & Only dopamine and serotonin partial agonist FDA approved for the most common forms of depression—MDD (adjunctive) and bipolar I depression1‡
VRAYLAR is approved across 4 indications
years of real-world experience1
clinical trials inclusive
of all indications1§
clinical trial patients1
‖Since 2015. Inclusive of all indications. Source: IQVIA 09/23.
*In clinical trials, VRAYLAR + antidepressant reduced overall depressive symptoms. In the 6-week trial, mean change from baseline in MADRS total score was -14.1 (VRAYLAR 1.5 mg/day + ADT) vs -11.5 (placebo + ADT) P<0.05; -13.1 for VRAYLAR 3 mg/day + ADT (dose was not statistically significant). In the 8-week trial, mean change from baseline in MADRS total score was -14.6 (VRAYLAR 2-4.5 mg/day + ADT) vs -12.5 (placebo + ADT) P<0.05; -13.4 for VRAYLAR 1-2 mg/day + ADT (dose was not statistically significant).1,2
†The most common adverse reactions in 6-week adjunctive MDD studies (≥5% and at least twice that of placebo) were akathisia, nausea, and insomnia. In these studies, 4% of VRAYLAR-treated patients discontinued treatment due to an adverse reaction, versus 2% of placebo-treated patients.1,2 See additional safety information below.
‡The mechanism of action of cariprazine is unknown. However, the efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors.
§The most common adverse reactions observed in VRAYLAR trials (≥5% and at least twice the rate of placebo): major depressive disorder (two 6-week studies) (VRAYLAR 1.5 mg/day + ADT or 3 mg/day + ADT vs placebo + ADT)— akathisia (7%, 10% vs 2%), nausea (7%, 6% vs 3%), and insomnia (9%, 10% vs 5%); bipolar I depression (VRAYLAR 1.5 mg/day or 3 mg/day vs placebo)-nausea (7%, 7% vs 3%), akathisia (6%, 10% vs 2%), restlessness (2%, 7% vs 3%), and EPS (4%, 6% vs 2%); bipolar I mania (VRAYLAR 3-6 mg/day vs placebo)—EPS (26% vs 12%), akathisia (20% vs 5%), vomiting (10% vs 4%), dyspepsia (7% vs 4%), somnolence (7% vs 4%), and restlessness (7% vs 2%); schizophrenia (VRAYLAR 1.5-3 mg/day and 4.5-6 mg/day vs placebo)—EPS (15%, 19% vs 8%) and akathisia (9%, 13% vs 4%).1
ADT=antidepressant therapy; EPS=extrapyramidal symptoms; MDD=major depressive disorder.
VRAYLAR remains committed to supporting access and affordability for patients
of VRAYLAR patients pay $10 or less per prescription2
Covered on top national commercial plans2#:
- Express Scripts
- CVS Health/Caremark
- UnitedHealthcare
- TRICARE
- Cigna
- Elevance (Anthem)
- Aetna
- OptumRX
Source: MAT August 2023.
¶The objective of the systematic literature review of 71 articles published between January 2010 and August 2020 was to assess the impact of patient drug cost-sharing on medication adherence, clinical outcomes, resource utilization and health care costs. The analysis observed increased cost-sharing was associated with worse adherence (84% of studies), persistence (79% of studies), or discontinuation (58% of studies). Limitations include that the type (eg, deductible, coinsurance, and copay) and magnitude (eg, $5, $50, or >$5,000 deductible) of cost-sharing were not homogeneous and outcome definitions varied (eg, proportion of days covered, medication possession ratios, or specific thresholds for treatment adherence, etc), making comparisons across publications difficult.31
#Coverage requirements and benefit design vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
One card, two ways to save.
Talk to your patients about the VRAYLAR Savings Program.